麦考酚酸钠 英文品名Mycophenolate Sodium 名称来源USAN;2000-2004; 化学表述" CA登记号 分子式C17H19NaO6 结构式 品种类别4-hexenoicacid;6-(1;3-dihydro-4-hydroxy-6-methoxy7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-;mo;
Package insert / product label Generic name: mycophenolate mofetil Dosage form: capsule Drug class: Selective immunosuppressants J Code (medical billing code): J7517 (250 mg, oral)Medically reviewed by Drugs.com. Last updated on Oct 21, 2024.On...
1.1 Name MYCOPHENOLATE SODIUM 1.2 Synonyms (4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid sodium salt; 4-Hexenoic acid,6-(1,3-dihydro-4-hydroxy-6-Methoxy-7-Methyl-3-oxo-5-isobenzofuranyl)-4-Methyl-,sodiuM salt; 4-Hexenoic ...
mycophenolate sodium enteric-coated tablets 基本信息 活性成分(中) 麦考酚钠 活性成分(英) mycophenolate sodium 全球最高研发状态 上市 中国最高研发状态 上市 原研公司 novartis pharma gmbh 中国首次上市年份 / 首次上市国家 / 首次上市年份 / 治疗疾病 / 靶点 作用机制 inosine-5 atc l04aa06➜l 抗肿瘤药...
Filler G, Buffo I (2007) Safety considerations with mycophenolate sodium. Expert Opin Drug Saf 6(4):445–449. : 10.1517/14740338.6.4.445Filler G, Buffo I. Safety considerations with mycophenolate sodium. Expert Opin Drug Saf. 2007;6:445–9....
The drug product is an oral suspension that contains 200 mg of mycophenolate mofetil/mL. The pH of suspension is between 6 and 8. Inactive ingredients in MYHIBBIN include dibasic sodium phosphate, glycerin, methylparaben, monobasic sodium phosphate, polysorbate 80, propylparaben, purified water, ra...
Mycophenolate mofetil 250 mg capsules:black iron oxide, colloidal silicon dioxide, croscarmellose sodium, FD&C Blue No. 2, gelatin, magnesium stearate, microcrystalline cellulose, pregelatinized starch (corn), red iron oxide, sodium lauryl sulfate, titanium dioxide and yellow iron oxide. In addition, ...
5 mg. Sodium hydroxide may have been used in the manufacture of CellCept Intravenous to adjust the pH. Reconstitution and dilution with 5% Dextrose Injection USP yields a slightly yellow solution of mycophenolate mofetil, 6 mg/mL. (For detailed method of preparation, seeDOSAGE AND ADMINISTRATION)...
A pharmaceutical composition according to claim 1 wherein themycophenolate salt is a mono-sodium salt.NUM 6.PAR 6. A pharmaceutical composition according to claim 2 wherein themycophenolate salt is a mono-sodium salt.NUM 7.PAR 7. A method according to claim 3 wherein the mycophenolate salt ...
Process for modifying the crystal habit of an acicular drug crystal wherein the acicular drug substance is a mycophenolate sodium salt, comprising suspending said crystalline drug substance in a methanol/water solvent and subjecting said suspension to a temperature oscillation, wherein the crystal ...